Genprex (GNPX) 10-Q13 Nov 242024 Q3 Quarterly reportFinancial data

Company Profile

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2024	Nov. 05, 2024
Document Information [Line Items]
Entity Central Index Key	0001595248
Entity Registrant Name	Genprex, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-38244
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	90-0772347
Entity Address, Address Line One	3300 Bee Cave Road, #650-227
Entity Address, City or Town	Austin
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78746
City Area Code	512
Local Phone Number	537-7997
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	GNPX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		8,508,068

Condensed Balance Sheets (Curre

Condensed Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 1,488,281	$ 6,737,629
Prepaid expenses and other	429,222	794,138
Total current assets	1,917,503	7,531,767
Property and equipment, net	463	7,859
Other non-current assets:
Security deposits	0	10,000
Research and development supplies	1,989,299	2,347,488
Intellectual property, net	0	773,478
Total other assets	1,989,299	3,130,966
Total assets	3,907,265	10,670,592
Current liabilities:
Accounts payables	1,304,121	1,397,610
Other current liabilities	938,173	1,856,598
Total current liabilities	2,242,294	3,254,208
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	0	0
Common stock $0.001 par value: 200,000,000 shares authorized; 5,489,152 and 1,485,902 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	5,489	1,486
Additional paid-in capital	152,128,463	141,103,178
Accumulated deficit	(150,468,981)	(133,688,280)
Total stockholders’ equity	1,664,971	7,416,384
Total liabilities and stockholders’ equity	$ 3,907,265	$ 10,670,592

Condensed Balance Sheets (Cur_2

Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	5,489,152	1,485,902
Common stock, shares outstanding (in shares)	5,489,152	1,485,902

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
Condensed Statements of Operations (Unaudited) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating expenses:
Depreciation	$ 1,272	$ 3,724	$ 6,230	$ 11,578
Research and development	2,756,081	4,616,546	7,696,982	13,903,611
General and administrative	1,566,085	3,166,057	9,135,225	11,173,643
Total operating expenses	4,323,438	7,786,327	16,838,437	25,088,832
Operating loss	(4,323,438)	(7,786,327)	(16,838,437)	(25,088,832)
Interest income	8,080	51,391	58,851	175,413
Realized loss	(629)	(13,307)	(1,115)	(17,790)
Net loss	$ (4,315,987)	$ (7,748,243)	$ (16,780,701)	$ (24,931,209)
Net loss per share—basic and diluted (in dollars per share)	$ (1.23)	$ (5.36)	$ (6.9)	$ (18.77)
Weighted average number of common shares—basic and diluted (in shares)	3,499,802	1,445,172	2,431,695	1,327,930

Condensed Statements of Changes

Condensed Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2022	1,202,677
Balance at Dec. 31, 2022	$ 1,203	$ 125,101,356	$ (102,827,819)	$ 22,274,740
Issuance of common stock, pre-funded warrants, and warrants for cash, net of issuance costs (in shares)	96,581
Issuance of common stock, pre-funded warrants, and warrants for cash, net of issuance costs	$ 96	4,080,684	0	4,080,780
Issuance of common stock for services (in shares)	125
Issuance of common stock for services	$ 0	21,885	0	21,885
Share-based compensation	0	1,310,230	0	1,310,230
Net loss	$ 0	0	(9,202,774)	(9,202,774)
Balance (in shares) at Mar. 31, 2023	1,299,383
Balance at Mar. 31, 2023	$ 1,299	130,514,155	(112,030,593)	18,484,861
Balance (in shares) at Dec. 31, 2022	1,202,677
Balance at Dec. 31, 2022	$ 1,203	125,101,356	(102,827,819)	22,274,740
Net loss				(24,931,209)
Balance (in shares) at Sep. 30, 2023	1,485,777
Balance at Sep. 30, 2023	$ 1,486	140,063,035	(127,759,028)	12,305,493
Balance (in shares) at Mar. 31, 2023	1,299,383
Balance at Mar. 31, 2023	$ 1,299	130,514,155	(112,030,593)	18,484,861
Issuance of common stock, pre-funded warrants, and warrants for cash, net of issuance costs	$ 0	0	0	0
Issuance of common stock for services (in shares)	125
Issuance of common stock for services	$ 1	4,399	0	4,400
Share-based compensation	0	1,541,805	0	1,541,805
Net loss	$ 0	0	(7,980,192)	(7,980,192)
Balance (in shares) at Jun. 30, 2023	1,299,508
Balance at Jun. 30, 2023	$ 1,300	132,060,359	(120,010,785)	12,050,874
Issuance of common stock, pre-funded warrants, and warrants for cash, net of issuance costs	$ 186	6,512,407	0	6,512,593
Issuance of common stock for services (in shares)	125
Issuance of common stock for services	$ 0	4,795	0	4,795
Share-based compensation	0	1,485,474	0	1,485,474
Net loss	$ 0	0	(7,748,243)	(7,748,243)
Balance (in shares) at Sep. 30, 2023	1,485,777
Balance at Sep. 30, 2023	$ 1,486	140,063,035	(127,759,028)	12,305,493
Balance (in shares) at Dec. 31, 2023	1,485,902
Balance at Dec. 31, 2023	$ 1,486	141,103,178	(133,688,280)	7,416,384
Issuance of common stock, pre-funded warrants, and warrants for cash, net of issuance costs (in shares)	323,474
Issuance of common stock, pre-funded warrants, and warrants for cash, net of issuance costs	$ 323	6,792,876	0	6,793,199
Issuance of common stock for services (in shares)	36,375
Issuance of common stock for services	$ 36	180,684	0	180,720
Company issued rounding of street name accounts for reverse stock split (in shares)	64,690
Company issued rounding of street name accounts for reverse stock split	$ 65	(65)	0	0
RSUs conversion to common stock (in shares)	12,145
RSUs conversion to common stock	$ 13	(13)	0	0
Share-based compensation	0	335,246	0	335,246
Net loss	$ 0	0	(5,968,869)	(5,968,869)
Balance (in shares) at Mar. 31, 2024	1,922,586
Balance at Mar. 31, 2024	$ 1,923	148,411,906	(139,657,149)	8,756,680
Balance (in shares) at Dec. 31, 2023	1,485,902
Balance at Dec. 31, 2023	$ 1,486	141,103,178	(133,688,280)	$ 7,416,384
Company issued rounding of street name accounts for reverse stock split (in shares)				64,690
Net loss				$ (16,780,701)
Balance (in shares) at Sep. 30, 2024	5,489,152
Balance at Sep. 30, 2024	$ 5,489	152,128,463	(150,468,981)	1,664,971
Balance (in shares) at Mar. 31, 2024	1,922,586
Balance at Mar. 31, 2024	$ 1,923	148,411,906	(139,657,149)	8,756,680
Issuance of common stock, pre-funded warrants, and warrants for cash, net of issuance costs (in shares)	608,671
Issuance of common stock, pre-funded warrants, and warrants for cash, net of issuance costs	$ 609	20,153	0	20,762
Issuance of common stock for services (in shares)	5,000
Issuance of common stock for services	$ 5	14,845	0	14,850
RSUs conversion to common stock (in shares)	19,478
RSUs conversion to common stock	$ 19	(19)	0	0
Share-based compensation	0	2,049,103	0	2,049,103
Net loss	$ 0	0	(6,495,845)	(6,495,845)
Balance (in shares) at Jun. 30, 2024	2,555,735
Balance at Jun. 30, 2024	$ 2,556	150,495,988	(146,152,994)	4,345,550
Issuance of common stock, pre-funded warrants, and warrants for cash, net of issuance costs (in shares)	2,928,417
Issuance of common stock, pre-funded warrants, and warrants for cash, net of issuance costs	$ 2,928	1,212,254	0	1,215,182
Issuance of common stock for services (in shares)	5,000
Issuance of common stock for services	$ 5	9,645	0	9,650
Share-based compensation	0	410,576	0	410,576
Net loss	$ 0	0	(4,315,987)	(4,315,987)
Balance (in shares) at Sep. 30, 2024	5,489,152
Balance at Sep. 30, 2024	$ 5,489	$ 152,128,463	$ (150,468,981)	$ 1,664,971

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
Condensed Statements of Cash Flows (Unaudited) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (16,780,701)	$ (24,931,209)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	6,230	11,578
Share-based compensation and issuance of stock for services	3,000,145	4,368,589
Intellectual property	773,478	0
Changes in operating assets and liabilities:
Accounts receivable	0	34,852
Prepaid expenses and other	374,916	(656,871)
Research and development supplies	358,189	(129,523)
Accounts payable	(93,488)	736,266
Other current liabilities	(918,427)	791,578
Net cash used in operating activities	(13,279,658)	(19,774,740)
Cash flows from investing activities:
Disposals of property and equipment	1,167	0
Additions to intellectual property	0	(61,383)
Net cash provided by (used in) investing activities	1,167	(61,383)
Cash flows from financing activities:
Net proceeds from issuances of common stock, pre-funded warrants, and warrants	8,029,143	10,593,373
Net cash provided by financing activities	8,029,143	10,593,373
Net decrease in cash and cash equivalents	(5,249,348)	(9,242,750)
Cash and cash equivalents, beginning of period	6,737,629	20,954,069
Cash and cash equivalents, end of period	$ 1,488,281	$ 11,711,319

Note 1 - Description of Busines

Note 1 - Description of Business and Basis of Presentation	9 Months Ended
Note 1 - Description of Business and Basis of Presentation	Sep. 30, 2024
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1 Unless the context requires otherwise, references to “Genprex,” the “Company,” “we,” “us” or “our” in this Quarterly Report on Form 10 April 2009, 1 may 2 Oncology Platform Genprex’s lead oncology drug candidate, Reqorsa® ( quaratusugene ozeplasmid 001, The TUSC2 one 3 August 2022, three TUSC2 Acclaim- 3 1 1/2 3 3 atezolizumab not January 2024, 1 3 first May 2024. October 2024, 0.09 1 no 3 0.12 1 2 second 2024, 0.12 first 1 3 May. thirty 30% two four may four three 30% one not three June 2023, 3 not August 2023, Acclaim- 2 2 pembrolizumab August 2024, 2 two one 1 Acclaim- 1 2a 1/2 1 1 osimertinib May 2023 1 1 1 1 2a no 1 2 0.12 1 erlotinib two 1 one second 41 30 one 26 19 2a first January 2024. 2a two August 2024, second 2a one 33 2b 1:1 19 2a 1 first 19 2a first 2025. 1 Diabetes Gene Therapy In diabetes, the Company has exclusively licensed from the University of Pittsburgh of the Commonwealth System of Higher Education (“University of Pittsburgh”) multiple technologies relating to the development of a gene therapy product for each of Type 1 2 1 2 Pdx1 002 1 2 002 1 may 002 2 003 not December 2023, first first 2025. October 2023, one August 2022 002 2 July 2023. Pdx1 1 2 September 2024, 002. 002, 2024, Capital Requirements, Liquidity and Going Concern Considerations The Company's unaudited condensed financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has sustained substantial losses from operations since inception and has no The Company recognizes that it must obtain additional capital resources to successfully commercialize its product candidates. To date, Genprex has received funding in the form of equity and debt, and the Company plans to seek additional funding in the future. However, no not may not Genprex believes that its current cash and cash equivalents will be sufficient to fund expenditure requirements for its necessary operations and expected clinical trial activities into December 2024. may no As a result of its recurring losses from operations and the need for additional financing to fund its operating and capital requirements, there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company’s ability to continue as a going concern. The unaudited condensed financial statements do not

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
Note 2 - Summary of Significant Accounting Policies	Sep. 30, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2 Genprex’s unaudited condensed financial statements have been prepared in accordance with US GAAP and the requirements of the United States Securities and Exchange Commission (the “SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that is normally required by US GAAP can be condensed or omitted. Accordingly, they do not December 31, 2023 December 31, 2023 2023 10 April 1, 2024 ( 10 The accompanying condensed financial statements are unaudited and include all adjustments (consisting of normal recurring adjustments) that management considers necessary for a fair presentation of Genprex’s condensed financial position and results of operations for the interim periods presented. The results of operations for the interim periods are not may A summary of Genprex’s significant accounting policies consistently applied in the preparation of the accompanying unaudited condensed financial statements follows. Change in Accounting Principle During the nine September 30, 2024 350 30. Reverse Stock Split On February 2, 2024, 1 not 4 Use of Estimates The preparation of Genprex’s unaudited condensed financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents Genprex considers all highly liquid short-term investments with an initial maturity of three $250,000 September 30, 2024 December 31, 2023 Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock, which includes common stock equivalents consisting of (i) 2,264,871 unexercised options granted by the Company’s board of directors and unexercised warrants to purchase shares of common stock, and (ii) 10,143 unvested restricted stock units granted by the Company’s board of directors representing the right upon vesting to receive shares of common stock as of September 30, 2024 Fair Value of Financial Instruments The carrying amounts reported in the condensed balance sheets for cash, money-market savings account, accounts receivable, and accounts payable approximate fair value because of the immediate or short-term maturity of these condensed financial instruments. Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from three five Research and Development Costs Research and development expenditures consist of costs incurred to conduct research, develop engineering materials for further study, and develop clinical strategies for current and future programs associated with the Company’s preclinical and Phase 1/2 Materials acquired to be used in clinical research, that have an alternative future use, are capitalized when the materials are acquired, and included in research and development supplies. These supplies are recognized as expense as they are consumed through use for testing or clinical activities, or have spoiled. The costs of materials that were acquired for a particular research and development activity and have no Research and development supplies purchased, valued at cost, and capitalized for future use were $1,989,299 and $2,347,488 at September 30, 2024 December 31, 2023 Intellectual Property Intellectual property consists of legal and related costs associated with patents, trademarks, and other proprietary technology and rights developed, acquired, or licensed by Genprex. Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These patent-related legal costs are reported as a component of general and administrative expenses. Accounting for Stock-Based Compensation Genprex uses the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors. The Company measures options granted at fair value determined as of the grant date and recognizes the expense over the periods in which the options vest or are expected to vest and related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period. Long-Lived Assets Genprex reviews long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not three nine September 30, 2024 2023, no Recent Accounting Developments Accounting pronouncements issued but not September 30, 2024 not In November 2023, 2023 07, 280 December 15, 2023, December 15, 2024, 2023 07 In December 2023, 2023 09, 740 December 15, 2024, 2023 09

Note 3 - Intellectual Property

Note 3 - Intellectual Property	9 Months Ended
Note 3 - Intellectual Property	Sep. 30, 2024
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	Note 3 As of September 30, 2024 University of Pittsburgh On February 11, 2020, 1 2 first August 17, 2022, November 3, 2022, 1 7 On November 22, 2022, 1 On December 29, 2022, Pdx1 2 On July 14, 2023, 1 2 Pdx1 The University of Texas MD Anderson Cancer Center On May 4, 2020,

Note 4 - Equity

Note 4 - Equity	9 Months Ended
Note 4 - Equity	Sep. 30, 2024
Notes to Financial Statements
Equity [Text Block]	Note 4 Reverse Stock Split At Genprex’s special meeting of stockholders held on December 14, 2023, not 1 10 not 1 50, January 19, 2024, 1 February 2, 2024. not Registered Direct Offerings On March 1, 2023, five may On July 21, 2023, July 18, 2028. may On March 21, 2024, “March 2024 “March 2024 March 2024 March 2024 March 2024 March 2024 March 2024 five March 2024 March 2023 July 2023, March 1, 2028 July 21, 2028 five March 2024 September 30, 2024 March 2024 At-The-Market Offering On December 13, 2023, “2023 may 2023 may 3 No. 333 271386 April 21, 2023, June 9, 2023. three three September 30, 2024 2023 nine September 30, 2024 2023 three September 30, 2024 On November 18, 2022, “2022 3 No. 333 239134 not 2022 three September 30, 2023 nine September 30, 2023 2022 December 12, 2023, 2022 December 13, 2023. Stock Issuances During the three September 30, 2024 March 2024 2023 During the nine September 30, 2024 March 2024 2023 March 2024 three September 30, 2024 During the three September 30, 2023 July 2023 nine September 30, 2023 three September 30, 2023 2022 March 2023 July 2023 three September 30, 2023 Preferred Stock Genprex is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.001 per share, none September 30, 2024 December 31, 2023 Common Stock Genprex is authorized to issue 200,000,000 shares of common stock with a par value of $0.001 per share, all of which are voting common stock. There were 5,489,152 and 1,485,902 shares of its common stock outstanding as of September 30, 2024 December 31, 2023 Common Stock Purchase Warrants Common stock purchase warrant activity for the three nine September 30, 2024 2023, 2024 2023 Number of Weighted Average Number of Weighted Average Warrants Exercise Price Warrants Exercise Price Outstanding at January 1, 346,440 $ 57.79 53,695 $ 172.81 Warrants issued 3,011,751 2.26 95,989 44.17 Warrants cancelled or expired — — 960 250.00 Outstanding at March 31, 3,358,191 $ 5.93 148,724 $ 64.01 Warrants exercised 598,112 0.00 — — Outstanding at June 30, 2,760,079 $ 7.22 148,724 $ 64.01 Warrants issued — — 200,284 20.68 Warrants exercised 779,000 0.00 — — Outstanding at September 30, 1,981,079 $ 10.05 349,008 $ 39.14 The Company (i) did not March 2024 three September 30, 2024 nine September 30, 2024 March 21, 2024, March 2023 July 2023, five March 2024 March 2024 three September 30, 2024 three nine September 30, 2024 not 2024 September 30, 2024 The Company issued (i) warrants to purchase up to an aggregate of 3,500 shares of common stock to service providers at exercise prices ranging from $26.00 to $37.94 per share, the fair market value of a share of common stock on the date of issuance, (ii) warrants to purchase up to 185,644 shares of common stock to accredited healthcare-focused institutional investors in connection with the registered direct offering completed on July 21, 2023, July 21, 2023, three September 30, 2023 nine September 30, 2023 March 2018 ( three September 30, 2023, three nine September 30, 2023, As of September 30, 2024 five three nine September 30, 2024 2023: Three Months Ended September 30, 2024 Nine Months Ended September 30, 2024 Three Months Ended September 30, 2023 Nine Months Ended September 30, 2023 Expected term (in years): — 2.5 2.5 - 3.0 2.5 - 3.0 Risk-free rate: — 4.52% 5.33% - 5.52% 4.99% - 5.52% Volatility: — 87.49% 83.42% 83.14% - 83.42% Dividend yield: — 0% 0% 0% 2018 The Company’s board of directors and stockholders have approved and adopted the Genprex 2018 “2018 April 3, 2018. 2018 422 1986, may may A total of 104,000 shares of common stock were initially available under the 2018 not 2009 “2009 No 2009 In addition, the number of shares of common stock reserved for issuance under the 2018 January 1 January 1, 2019, December 31 2018 On January 1, 2023 2024, 2018 September 30, 2024 2018 2018 The Company’s board of directors and stockholders approved and adopted the Genprex 2018 April 3, 2018. not may January 1 January 1, 2019, December 31 not shares reserved for issuance under the ESPP on January 1, 2024 . Stock Options As of September 30, 2024 2018 2021 2023. ten no three nine September 30, 2024 three nine September 30, 2024 2023, Three Months Ended September 30, 2024 Nine Months Ended September 30, 2024 Three Months Ended September 30, 2023 Nine Months Ended September 30, 2023 Expected term (in years): — — 6.0 6.0 Risk-free rate: — — 5.37% 4.60% - 5.37% Volatility: — — 83.42% 83.14% - 83.42% Dividend yield: — — 0% 0% The Company did not three nine September 30, 2024 three September 30, 2024 nine September 30, 2024 three September 30, 2024 During the three September 30, 2023 nine September 30, 2023 three September 30, 2023 The weighted average remaining contractual term for the outstanding options at September 30, 2024 December 31, 2023 Stock option activity for the three nine September 30, 2024 2023, 2024 2023 Number of Weighted Average Number of Weighted Average Options Exercise Price Options Exercise Price Outstanding at January 1, 285,883 $ 121.11 284,377 $ 123.19 Options granted — — 2,063 57.23 Options expired or cancelled 438 32.40 — — Outstanding at March 31, 285,445 $ 121.25 286,440 $ 122.72 Options granted — — 1,188 34.17 Options expired or cancelled 1,193 14.75 — — Outstanding at June 30, 284,252 $ 121.52 287,628 $ 122.35 Options granted — — 5,000 18.00 Options exercised — — 500 11.92 Options expired or cancelled 460 55.25 308 124.64 Outstanding at September 30, 283,792 $ 121.63 291,820 $ 120.75 Restricted Stock Units During the three September 30, 2024 not nine September 30, 2024 three September 30, 2024 During the three September 30, 2023 not nine September 30, 2023 A summary of the RSU activity under the 2018 three nine September 30, 2024 2023, 2024 2023 Number of Weighted Average Number of Weighted Average Units Grant Date Fair Value Units Grant Date Fair Value Outstanding at January 1, 51,862 $ 59.48 — — Restricted stock units granted — — 47,834 66.00 Restricted stock units vested 12,145 66.00 — — Restricted stock units forfeited or cancelled 6,086 66.00 — — Outstanding at March 31, 33,631 $ 55.95 47,834 $ 66.00 Restricted stock units granted — — 9,285 29.60 Restricted stock units vested 19,478 48.65 — — Restricted stock units forfeited or cancelled 4,010 66.00 — — Outstanding at June 30, 10,143 $ 66.00 57,119 $ 60.08 Restricted stock units forfeited or cancelled 9 66.00 257 66.00 Outstanding at September 30, 10,134 $ 66.00 56,862 $ 60.06 Share-Based Compensation For the three nine September 30, 2024 September 30, 2024 not three September 30, 2024 For the three nine September 30, 2023 September 30, 2023 not three September 30, 2023 As of September 30, 2024 no one not may

Note 5 - 401(k) Savings Plan

Note 5 - 401(k) Savings Plan	9 Months Ended
Note 5 - 401(k) Savings Plan	Sep. 30, 2024
Notes to Financial Statements
Defined Contribution Plan [Text Block]	Note 5 401 In 2022, 401 “401 401 401 401 three nine September 30, 2024 401 three nine September 30, 2023

Note 6 - Related Party Transact

Note 6 - Related Party Transactions	9 Months Ended
Note 6 - Related Party Transactions	Sep. 30, 2024
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 6 Introgen Research Institute Introgen Research Institute (“IRI”) is a Texas-based technology company formed by Rodney Varner, the Company’s former President, Chief Executive Officer and Chairman of the Board, who served in such capacity until his death on May 7, 2024, April 2009, August 2012, 2011 7 no September 30, 2024 December 31, 2023

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	9 Months Ended
Note 7 - Commitments and Contingencies	Sep. 30, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 7 Commitments MD Anderson Cancer Center In July 2018, two May 2022 August 2022, three “August 2022 NPRL2 June 7, 2024, August 2022 six three September 30, 2024 nine September 30, 2024 September 30, 2024 In 2011, 1994 On March 3, 2021, May 4, 2020, six one TUSC2 TUSC2 five six one five three September 30, 2024 2023, nine September 30, 2024 2023, September 30, 2024 National Institutes of Health Genprex has a royalty obligation to the National Institutes of Health to be paid upon the Company’s receipt of FDA approval using NIH technology. The $240,000 contingent obligation, which increases annually by $20,000, and is $380,000 and $360,000 as of September 30, 2024 December 31, 2023, University of Pittsburgh Pursuant to an exclusive license agreement dated February 11, 2020, August 17, 2022, November 3, 2022, first three first first 1 20 first three September 30, 2024 2023, nine September 30, 2024 2023, September 30, 2024 Pursuant to an exclusive license agreement dated November 22, 2022, first three first first 1 20 first no three nine September 30, 2024 three nine September 30, 2023 September 30, 2024 Pursuant to an exclusive license agreement dated December 29, 2022, first three first first 2 20 first no three nine September 30, 2024 three nine September 30, 2023 September 30, 2024 Pursuant to an exclusive license agreement dated July 14, 2023, first second third fourth fourth first first 1 2 20 first three September 30, 2024 2023, nine September 30, 2024 2023, September 30, 2024 Contract Development and Manufacturing Organization Genprex entered into a three July 2022, January 2023 March 2023, April 2, 2024, June 30, 2024, no nine September 30, 2024 2023, Contingencies From time to time, the Company may not

Note 8 - Subsequent Events

Note 8 - Subsequent Events	9 Months Ended
Note 8 - Subsequent Events	Sep. 30, 2024
Notes to Financial Statements
Subsequent Events [Text Block]	Note 8 The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10 no 10 Share Issuances On October 1, 2024, September 30, 2024, 2023

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2024
Insider Trading Arr Line Items
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
Significant Accounting Policies (Policies)	Sep. 30, 2024
Accounting Policies [Abstract]
Change in Accounting Principle [Policy Text Block]	Change in Accounting Principle During the nine September 30, 2024 350 30.
Reverse Stock Split [Policy Text Block]	Reverse Stock Split On February 2, 2024, 1 not 4
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of Genprex’s unaudited condensed financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents Genprex considers all highly liquid short-term investments with an initial maturity of three $250,000 September 30, 2024 December 31, 2023
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock, which includes common stock equivalents consisting of (i) 2,264,871 unexercised options granted by the Company’s board of directors and unexercised warrants to purchase shares of common stock, and (ii) 10,143 unvested restricted stock units granted by the Company’s board of directors representing the right upon vesting to receive shares of common stock as of September 30, 2024
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The carrying amounts reported in the condensed balance sheets for cash, money-market savings account, accounts receivable, and accounts payable approximate fair value because of the immediate or short-term maturity of these condensed financial instruments.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from three five
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs Research and development expenditures consist of costs incurred to conduct research, develop engineering materials for further study, and develop clinical strategies for current and future programs associated with the Company’s preclinical and Phase 1/2 Materials acquired to be used in clinical research, that have an alternative future use, are capitalized when the materials are acquired, and included in research and development supplies. These supplies are recognized as expense as they are consumed through use for testing or clinical activities, or have spoiled. The costs of materials that were acquired for a particular research and development activity and have no Research and development supplies purchased, valued at cost, and capitalized for future use were $1,989,299 and $2,347,488 at September 30, 2024 December 31, 2023
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Intellectual Property Intellectual property consists of legal and related costs associated with patents, trademarks, and other proprietary technology and rights developed, acquired, or licensed by Genprex. Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These patent-related legal costs are reported as a component of general and administrative expenses.
Share-Based Payment Arrangement [Policy Text Block]	Accounting for Stock-Based Compensation Genprex uses the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors. The Company measures options granted at fair value determined as of the grant date and recognizes the expense over the periods in which the options vest or are expected to vest and related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-Lived Assets Genprex reviews long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not three nine September 30, 2024 2023, no
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Developments Accounting pronouncements issued but not September 30, 2024 not In November 2023, 2023 07, 280 December 15, 2023, December 15, 2024, 2023 07 In December 2023, 2023 09, 740 December 15, 2024, 2023 09

Note 4 - Equity (Tables)

Note 4 - Equity (Tables)	9 Months Ended
Note 4 - Equity (Tables)	Sep. 30, 2024
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	2024 2023 Number of Weighted Average Number of Weighted Average Warrants Exercise Price Warrants Exercise Price Outstanding at January 1, 346,440 $ 57.79 53,695 $ 172.81 Warrants issued 3,011,751 2.26 95,989 44.17 Warrants cancelled or expired — — 960 250.00 Outstanding at March 31, 3,358,191 $ 5.93 148,724 $ 64.01 Warrants exercised 598,112 0.00 — — Outstanding at June 30, 2,760,079 $ 7.22 148,724 $ 64.01 Warrants issued — — 200,284 20.68 Warrants exercised 779,000 0.00 — — Outstanding at September 30, 1,981,079 $ 10.05 349,008 $ 39.14
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended September 30, 2024 Nine Months Ended September 30, 2024 Three Months Ended September 30, 2023 Nine Months Ended September 30, 2023 Expected term (in years): — 2.5 2.5 - 3.0 2.5 - 3.0 Risk-free rate: — 4.52% 5.33% - 5.52% 4.99% - 5.52% Volatility: — 87.49% 83.42% 83.14% - 83.42% Dividend yield: — 0% 0% 0% Three Months Ended September 30, 2024 Nine Months Ended September 30, 2024 Three Months Ended September 30, 2023 Nine Months Ended September 30, 2023 Expected term (in years): — — 6.0 6.0 Risk-free rate: — — 5.37% 4.60% - 5.37% Volatility: — — 83.42% 83.14% - 83.42% Dividend yield: — — 0% 0%
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	2024 2023 Number of Weighted Average Number of Weighted Average Options Exercise Price Options Exercise Price Outstanding at January 1, 285,883 $ 121.11 284,377 $ 123.19 Options granted — — 2,063 57.23 Options expired or cancelled 438 32.40 — — Outstanding at March 31, 285,445 $ 121.25 286,440 $ 122.72 Options granted — — 1,188 34.17 Options expired or cancelled 1,193 14.75 — — Outstanding at June 30, 284,252 $ 121.52 287,628 $ 122.35 Options granted — — 5,000 18.00 Options exercised — — 500 11.92 Options expired or cancelled 460 55.25 308 124.64 Outstanding at September 30, 283,792 $ 121.63 291,820 $ 120.75
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]	2024 2023 Number of Weighted Average Number of Weighted Average Units Grant Date Fair Value Units Grant Date Fair Value Outstanding at January 1, 51,862 $ 59.48 — — Restricted stock units granted — — 47,834 66.00 Restricted stock units vested 12,145 66.00 — — Restricted stock units forfeited or cancelled 6,086 66.00 — — Outstanding at March 31, 33,631 $ 55.95 47,834 $ 66.00 Restricted stock units granted — — 9,285 29.60 Restricted stock units vested 19,478 48.65 — — Restricted stock units forfeited or cancelled 4,010 66.00 — — Outstanding at June 30, 10,143 $ 66.00 57,119 $ 60.08 Restricted stock units forfeited or cancelled 9 66.00 257 66.00 Outstanding at September 30, 10,134 $ 66.00 56,862 $ 60.06

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Details Textual)		3 Months Ended		9 Months Ended
	Feb. 02, 2024	Sep. 30, 2024 USD ($) shares	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Cash, Uninsured Amount		$ 1,238,246		$ 1,238,246		$ 6,490,117
Research and Development Assets, Current		1,989,299		1,989,299		$ 2,347,488
Impairment, Long-Lived Asset, Held-for-Use		$ 0	$ 0	$ 0	$ 0
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)		3 years		3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)		5 years		5 years
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) \| shares		2,264,871
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) \| shares		10,143
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	40

Note 3 - Intellectual Property

Note 3 - Intellectual Property (Details Textual)	9 Months Ended
Note 3 - Intellectual Property (Details Textual)	Sep. 30, 2024
Number of Granted Patents	22
Number of Pending Patent Applications	26

Note 4 - Equity (Details Textua

Note 4 - Equity (Details Textual)										1 Months Ended	3 Months Ended							6 Months Ended		9 Months Ended		12 Months Ended
Note 4 - Equity (Details Textual)	Mar. 21, 2024 USD ($) $ / shares shares	Feb. 02, 2024	Jan. 01, 2024 shares	Dec. 31, 2023 $ / shares shares	Jul. 21, 2023 USD ($) $ / shares shares	Mar. 01, 2023 USD ($) $ / shares shares	Jan. 01, 2023 shares	Nov. 18, 2022 USD ($)	Apr. 03, 2018 shares	Mar. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2024 USD ($) shares	Sep. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) $ / shares shares	Mar. 31, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2023 USD ($) $ / shares shares	Mar. 31, 2023 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 $ / shares shares	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) $ / shares shares	Dec. 31, 2024 USD ($)	Dec. 31, 2023 $ / shares shares	Jul. 31, 2023 $ / shares	Dec. 31, 2022 $ / shares shares
Warrants and Rights Outstanding, Term (Year)												5 years								5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares				$ 57.79						$ 5.93		$ 10.05	$ 7.22	$ 5.93	$ 39.14	$ 64.01	$ 64.01	$ 7.22	$ 64.01	$ 10.05	$ 39.14		$ 57.79		$ 172.81
Class of Warrant or Right, Exercised During Period (in shares)												779,000	598,112		0	0
Proceeds from Issuance of Common Stock \| $																				$ 8,029,143	$ 10,593,373
Stock Issued During Period, Value, Issued for Services \| $												$ 9,650	$ 14,850	$ 180,720	$ 4,795	$ 4,400	$ 21,885
Stock Issued During Period, Shares, Reverse Stock Splits (in shares)																				64,690
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)												0			500
Preferred Stock, Shares Authorized (in shares)				10,000,000								10,000,000								10,000,000			10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares				$ 0.001								$ 0.001								$ 0.001			$ 0.001
Preferred Stock, Shares Outstanding (in shares)				0								0								0			0
Common Stock, Shares Authorized (in shares)				200,000,000								200,000,000								200,000,000			200,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares				$ 0.001								$ 0.001								$ 0.001			$ 0.001
Common Stock, Shares, Outstanding (in shares)				1,485,902								5,489,152								5,489,152			1,485,902
Class of Warrant or Right, Issued in Period (in shares)												0		3,011,751	200,284		95,989
Class of Warrant or Right, Cancelled During Period (in shares)														0			960				960
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)				285,883						285,445		283,792	284,252	285,445	291,820	287,628	286,440	284,252	287,628	283,792	291,820		285,883		284,377
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)																				10 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share) \| $ / shares				$ 121.11						$ 121.25		$ 121.63	$ 121.52	$ 121.25	$ 120.75	$ 122.35	$ 122.72	$ 121.52	$ 122.35	$ 121.63	$ 120.75		$ 121.11		$ 123.19
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)												0	0	0	5,000	1,188	2,063			0	8,251
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period (in shares)												460	1,193	438	308	0	0			2,091	308
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share) \| $ / shares												$ 55.25	$ 14.75	$ 32.4	$ 124.64	$ 0	$ 0
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) \| $ / shares												0	$ 0	$ 0	18	$ 34.17	$ 57.23
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share) \| $ / shares												$ 0			$ 11.92
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)																				5 years 4 months 9 days			6 years 1 month 17 days
Class of Warrant or Right, Outstanding (in shares)				346,440						3,358,191		1,981,079	2,760,079	3,358,191	349,008	148,724	148,724	2,760,079	148,724	1,981,079	349,008		346,440		53,695
The 2018 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)			74,294				60,132		104,000											96,617
Share Based Compensation Arrangement By Share Based Payment Award, Percentage Applied on Outstanding Shares of Common Stock For Automatically Increase on Each Year									5%
The 2009 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)									65,719
The 2018 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award, Percentage Applied on Outstanding Shares of Common Stock For Automatically Increase on Each Year									2%
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)									5,202
Excluding the 2018 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)												25,417								25,417
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)													19,478	12,145			0		0	31,623
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested \| $																				$ 96,460
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)												0			0						57,119
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures (in shares)												9			257					275
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation (in shares)												9,830
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures (in shares)																				31,623
Performance Shares [Member]
Share-based Payment Arrangement, Expense, Future Milestone \| $																		$ 300,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)												0								0
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Expense \| $												$ 400,000			$ 1,500,000					$ 2,700,000	$ 4,400,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount \| $												600,000			5,900,000					$ 600,000	$ 5,900,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)																				6 months 29 days	1 year 4 months 13 days
Share-Based Payment Arrangement, Option [Member] \| Research and Development Expense [Member]
Share-Based Payment Arrangement, Expense \| $												200,000			300,000					$ 500,000	$ 1,000,000
Share-Based Payment Arrangement, Option [Member] \| General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expense \| $												$ 200,000			1,200,000					$ 2,200,000	3,400,000
Scientific Advisory Board Chairman [Member]
Proceeds from Issuance of Common Stock \| $															$ 4,800						$ 17,150
Stock Issued During Period, Shares, Issued for Services (in shares)												5,000			125					10,125	375
Stock Issued During Period, Value, Issued for Services \| $												$ 9,650								$ 25,670
Service Providers [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)																				36,250
Stock Issued During Period, Value, Issued for Services \| $																				$ 179,550
Former Board Member [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)															500						500
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share) \| $ / shares															$ 12						$ 12
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares												$ 288.8								$ 288.8
Warrants or Rights, Fair Value Per Share (in dollars per share) \| $ / shares												185								$ 185
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)																				48 months
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share) \| $ / shares												392								$ 392
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share) \| $ / shares																				317.2
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share) \| $ / shares												59.6			142					80	142
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) \| $ / shares																					60.4
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares												4.09								4.09
Warrants or Rights, Fair Value Per Share (in dollars per share) \| $ / shares												1.21								$ 1.21
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)																				12 months
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share) \| $ / shares												18								$ 18
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share) \| $ / shares																				12.62
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share) \| $ / shares												$ 54.8			$ 88					$ 32.4	88
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) \| $ / shares																					$ 18
Warrants Issued with Registered Direct Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					185,644	95,239
Warrants and Rights Outstanding, Term (Year)					5 years	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares					$ 35.4	$ 44
Class of Warrant or Right, Issued in Period (in shares)					185,644
Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					11,140
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares	$ 5.2688				$ 50.5
Class of Warrant or Right, Issued in Period (in shares)	92,527				11,140
March 2024 Pre-Funded Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares	$ 0.0001
Stock Issued During Period, Shares, Issued Due to Exercise of Warrants (in shares)																				1,377,112
Class of Warrant or Right, Issued in Period (in shares)	1,377,112											779,000								598,112
March 2024 Pre-Funded Warrants [Member] \| Scientific Advisory Board Chairman [Member]
Stock Issued During Period, Shares, Issued Due to Exercise of Warrants (in shares)												779,000
March 2024 Pre-Funded Warrants [Member] \| Maximum [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	1,377,112
Class of Warrant or Right, Issued in Period (in shares)	1,542,112
March 2024 Common Warrants [Member]
Warrants and Rights Outstanding, Term (Year)	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares	$ 4.09
March 2024 Common Warrants [Member] \| Maximum [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	1,542,112
March 2024 Pre-Funded Warrant and Common Warrant [Member]
Class of Warrant or Right, Combined Purchase Price \| $	$ 4.2149
Amended Registered Direct Offering [Member]
Warrants and Rights Outstanding, Term (Year)	5 years																5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares	$ 4.09																$ 44							$ 35.4
Class of Warrant or Right, Amendment Price Per Warrant (in dollars per share) \| $ / shares	$ 0.125
Class of Warrant or Right, Exercised During Period (in shares)																				1,377,112
Class of Warrant or Right, Issued in Period (in shares)	194,248
Amended Registered Direct Offering [Member] \| Maximum [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																	194,248
Vesting of Warrants For Service Provider [Member]
Share-Based Payment Arrangement, Expense \| $												$ 2,281			$ 50,853					$ 18,039	$ 128,164
Vesting of Warrants For Service Provider [Member] \| Forecast [Member]
Share-Based Payment Arrangement, Expense \| $																						$ 0
Warrants Issued for Services [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)												1,981,079								1,981,079
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares												$ 10.05								$ 10.05
Class of Warrant or Right, Issued in Period (in shares)															3,500						4,250
Warrants Issued for Services [Member] \| Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares															$ 37.94						$ 37.94
Warrants Issued for Services [Member] \| Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares															26						26
Warrant For Service Provider 2 [Member] \| Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares															66						66
Warrant For Service Provider 2 [Member] \| Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares															$ 26						$ 26
Service Providers, Institutional Investors and Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)															292,023						292,023
Service Providers, Institutional Investors and Placement Agent Warrants [Member] \| Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares															$ 66						$ 66
Service Providers, Institutional Investors and Placement Agent Warrants [Member] \| Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares															$ 29.2						$ 29.2
Performance-based Warrant [Member]
Class of Warrant or Right, Outstanding (in shares)												1								1
Warrant, Nonvested Award, Cost Not yet Recognized, Amount \| $												$ 0.3								$ 0.3
Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	165,000					95,239
Equity Offering, Combined Purchase Price (in dollars per share) \| $ / shares	$ 4.215					$ 42
Proceeds from Issuance or Sale of Equity \| $						$ 3,600,000				$ 5.8
Payments of Stock Issuance Costs \| $						$ 400,000
July 2023 Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)					185,644
Proceeds from Issuance or Sale of Equity \| $					$ 6,700,000
Payments of Stock Issuance Costs \| $					$ 800,000
Shares Issued, Price Per Share (in dollars per share) \| $ / shares					$ 40.4
The 2022 ATM Facility [Member]
Stock Issued During Period, Shares, New Issues (in shares)																					1,342
Brokerage Commissions, Percentage of Gross Proceeds				3%				3%
Proceeds from Issuance of Common Stock \| $																					$ 78,355
The 2022 ATM Facility [Member] \| Maximum [Member]
Common Stock, Shares Authorized, Value \| $								$ 50,000,000
The 2023 ATM Facility [Member]
Stock Issued During Period, Shares, New Issues (in shares)												2,149,417								2,318,450
Proceeds from Issuance of Common Stock \| $												$ 1,215,105								$ 2,117,752
The 2023 ATM Facility [Member] \| Forecast [Member]
Stock Issued During Period, Shares, New Issues (in shares)											3,013,916
Proceeds from Issuance of Common Stock \| $											$ 1,286,014
March 2024 Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)																				165,000
Proceeds from Issuance of Common Stock \| $																				$ 5,800,000
July 2023 Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)															185,644
Proceeds from Issuance of Common Stock \| $															$ 6,700,000
March 2023 and July 2023 Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)																					280,883
Proceeds from Issuance of Common Stock \| $																					$ 10,500,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		40

Note 4 - Equity - Common Stock

Note 4 - Equity - Common Stock Purchase Warrant Activity (Details) - $ / shares	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Outstanding, number of warrants (in shares)	2,760,079	3,358,191	346,440	148,724	148,724	53,695	346,440	53,695
Outstanding, weighted average exercise price (in dollars per share)	$ 7.22	$ 5.93	$ 57.79	$ 64.01	$ 64.01	$ 172.81	$ 57.79	$ 172.81
Warrants issued, number of warrants (in shares)	0		3,011,751	200,284		95,989
Warrants issued, weighted average exercise price (in dollars per share)	$ 0		$ 2.26	$ 20.68		$ 44.17
Warrants cancelled or expired, number of warrants (in shares)			0			960		960
Warrants cancelled or expired, weighted average exercise price (in dollars per share)			$ 0			$ 250
Warrants exercised, number of warrants (in shares)	779,000	598,112		0	0
Warrants exercised, weighted average exercise price (in dollars per share)	$ 0	$ 0		$ 0	$ 0
Outstanding, number of warrants (in shares)	1,981,079	2,760,079	3,358,191	349,008	148,724	148,724	1,981,079	349,008
Outstanding, weighted average exercise price (in dollars per share)	$ 10.05	$ 7.22	$ 5.93	$ 39.14	$ 64.01	$ 64.01	$ 10.05	$ 39.14

Note 4 - Equity - Assumptions (

Note 4 - Equity - Assumptions (Details)	3 Months Ended		9 Months Ended
Note 4 - Equity - Assumptions (Details)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Expected term (in years): (Year)			2 years 6 months
Risk-free rate:	0%		4.52%
Volatility:	0%	83.42%	87.49%
Dividend yield:	0%	0%	0%	0%
Share-Based Payment Arrangement, Option [Member]
Expected term (in years): (Year)		6 years		6 years
Risk-free rate:	0%	5.37%	0%
Volatility:	0%	83.42%	0%
Dividend yield:	0%	0%	0%	0%
Minimum [Member]
Expected term (in years): (Year)		2 years 6 months		2 years 6 months
Risk-free rate:		5.33%		4.99%
Volatility:				83.14%
Minimum [Member] \| Share-Based Payment Arrangement, Option [Member]
Risk-free rate:				4.60%
Volatility:				83.14%
Maximum [Member]
Expected term (in years): (Year)		3 years		3 years
Risk-free rate:		5.52%		5.52%
Volatility:				83.42%
Maximum [Member] \| Share-Based Payment Arrangement, Option [Member]
Risk-free rate:				5.37%
Volatility:				83.42%

Note 4 - Equity - Stock Option

Note 4 - Equity - Stock Option Activity (Details) - $ / shares	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Outstanding, number of shares (in shares)	284,252	285,445	285,883	287,628	286,440	284,377	285,883	284,377
Outstanding, weighted average exercise price (in dollars per share)	$ 121.52	$ 121.25	$ 121.11	$ 122.35	$ 122.72	$ 123.19	$ 121.11	$ 123.19
Options granted, number of shares (in shares)	0	0	0	5,000	1,188	2,063	0	8,251
Options granted, weighted average exercise price (in dollars per share)	$ 0	$ 0	$ 0	$ 18	$ 34.17	$ 57.23
Options expired or cancelled, number of shares (in shares)	460	1,193	438	308	0	0	2,091	308
Options expired or cancelled, weighted average exercise price (in dollars per share)	$ 55.25	$ 14.75	$ 32.4	$ 124.64	$ 0	$ 0
Options exercised, number of shares (in shares)	0			500
Options exercised, weighted average exercise price (in dollars per share)	$ 0			$ 11.92
Outstanding, number of shares (in shares)	283,792	284,252	285,445	291,820	287,628	286,440	283,792	291,820
Outstanding, weighted average exercise price (in dollars per share)	$ 121.63	$ 121.52	$ 121.25	$ 120.75	$ 122.35	$ 122.72	$ 121.63	$ 120.75

Note 4 - Equity - Restricted St

Note 4 - Equity - Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	3 Months Ended					6 Months Ended	9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Mar. 31, 2023	Jun. 30, 2023	Sep. 30, 2024
Outstanding, shares (in shares)	10,143	33,631	51,862	57,119	0	0	51,862
Outstanding, weighted average grant date fair value (in dollars per share)	$ 66	$ 55.95	$ 59.48	$ 60.08	$ 0	$ 0	$ 59.48
Restricted stock units granted, shares (in shares)		0	0		47,834	9,285
Restricted stock units granted, weighted average grant date fair value (in dollars per share)		$ 0	$ 0		$ 66	$ 29.6
Restricted stock units vested, shares (in shares)		19,478	12,145		0	0	31,623
Restricted stock units vested, weighted average grant date fair value (in dollars per share)		$ 48.65	$ 66		$ 0	$ 0
Restricted stock units forfeited or cancelled, shares (in shares)	9	4,010	6,086	257	0	0
Restricted stock units forfeited or cancelled, weighted average grant date fair value (in dollars per share)	$ 66	$ 66	$ 66	$ 66	$ 0	$ 0
Outstanding, shares (in shares)	10,134	10,143	33,631	56,862	47,834	57,119	10,134
Outstanding, weighted average grant date fair value (in dollars per share)	$ 66	$ 66	$ 55.95	$ 60.06	$ 66	$ 60.08	$ 66

Note 5 - 401(k) Savings Plan (D

Note 5 - 401(k) Savings Plan (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
Note 5 - 401(k) Savings Plan (Details Textual) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Defined Contribution Plan, Cost	$ 31,930	$ 29,817	$ 105,848	$ 120,623

Note 7 - Commitments and Cont_2

Note 7 - Commitments and Contingencies (Details Textual) - USD ($)			1 Months Ended		3 Months Ended			5 Months Ended	9 Months Ended		12 Months Ended
	Jun. 30, 2024	Sep. 30, 2022	Jun. 30, 2024	Jul. 31, 2018	Sep. 30, 2024	Sep. 30, 2023	Mar. 31, 2017	Jun. 06, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2009	Jul. 14, 2023	Mar. 31, 2023	Dec. 29, 2022	Nov. 22, 2022	Mar. 03, 2021	Feb. 11, 2020
Costs and Expenses					$ 4,323,438	$ 7,786,327			$ 16,838,437	$ 25,088,832
License Agreement Terms [Member]
Costs and Expenses					0	0			50,000	45,000
Contract Payments Incurred and Paid					370,000
License Agreement Milestone Payment																	$ 6,150,000
National Institute of Health [Member]
Royalty on Sales, Percentage												1%
Royalty Term (Year)												21 years
Royalty Payment, Annual Minimum												$ 20,000
Payment for Contingent Consideration Liability, Operating Activities							$ 240,000
Contingent Payments Annual Increase							$ 20,000
Other Commitment					380,000				380,000		$ 360,000
Research Agreement [Member] \| MD Anderson [Member]
Long Term Contract, Estimated Cost		$ 2,900,000	$ 2.75	$ 2,000,000	2,760,000			$ 2,900,000
Long Term Contract, Quarterly Budget Allocated			$ 165,000					$ 240,000
Costs and Expenses					165,701				645,839
Contract Payments Incurred and Paid					1,200,000
License Agreement [Member] \| University of Pittsburgh [Member]
Licensing Fee, Amount																		$ 25,000
Annual Maintenance Fee, First Three Years, Amount																		25,000
Annual Maintenance Fee, After Year Three, Amount																		40,000
Annual Royalty Payment Per Year, Minimum																		$ 250,000
Share of Non-Royalty Sublicense Income, Percent																		20%
License Agreement [Member] \| University of Pittsburgh [Member] \| Dosing of First Human Patient in a Phase I Clinical Trial [Member]
Costs and Expenses					0	0			40,000	25,000
Contract Payments Incurred and Paid					150,000
Milestone Payment																		$ 3,975,000
License Agreement [Member] \| University of Pittsburgh [Member] \| Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 Diabetes [Member]
Costs and Expenses					0	0			0	25,000
Contract Payments Incurred and Paid					50,000
Licensing Fee, Amount															$ 25,000	$ 25,000
Annual Maintenance Fee, First Three Years, Amount																25,000
Annual Maintenance Fee, After Year Three, Amount																40,000
Annual Royalty Payment Per Year, Minimum																$ 250,000
Share of Non-Royalty Sublicense Income, Percent																20%
Milestone Payment																$ 3,975,000
License Agreement [Member] \| University of Pittsburgh [Member] \| Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 2 Diabetes [Member]
Costs and Expenses					0	0				25,000
Contract Payments Incurred and Paid					50,000						25,000
Licensing Fee, Amount											$ 25,000
Annual Maintenance Fee, First Three Years, Amount															25,000
Annual Maintenance Fee, After Year Three, Amount															40,000
Annual Royalty Payment Per Year, Minimum															$ 250,000
Share of Non-Royalty Sublicense Income, Percent															20%
Milestone Payment															$ 3,975,000
License Agreement [Member] \| University of Pittsburgh [Member] \| Represents Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 and 2 Diabetes [Member]
Costs and Expenses					0	$ 0			25,000	25,000
Contract Payments Incurred and Paid					$ 50,000
Annual Royalty Payment Per Year, Minimum													$ 250,000
Share of Non-Royalty Sublicense Income, Percent													20%
Milestone Payment													$ 4,225,000
Annual Maintenance Fee, Second and Third Year, Amount													50,000
Annual Maintenance Fee, Fourth Year, Amount													$ 100,000
License Agreement [Member] \| University of Pittsburgh [Member] \| Minimum [Member]
Royalty Percent, Licensed Technology Covered by Patent																		1.50%
License Agreement [Member] \| University of Pittsburgh [Member] \| Minimum [Member] \| Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 Diabetes [Member]
Royalty Percent, Licensed Technology Covered by Patent																1.50%
License Agreement [Member] \| University of Pittsburgh [Member] \| Minimum [Member] \| Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 2 Diabetes [Member]
Royalty Percent, Licensed Technology Covered by Patent															1.50%
License Agreement [Member] \| University of Pittsburgh [Member] \| Minimum [Member] \| Represents Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 and 2 Diabetes [Member]
Royalty Percent, Licensed Technology Covered by Patent													1.50%
License Agreement [Member] \| University of Pittsburgh [Member] \| Maximum [Member]
Royalty Percent, Licensed Technology Covered by Patent																		3%
License Agreement [Member] \| University of Pittsburgh [Member] \| Maximum [Member] \| Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 Diabetes [Member]
Royalty Percent, Licensed Technology Covered by Patent																3%
License Agreement [Member] \| University of Pittsburgh [Member] \| Maximum [Member] \| Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 2 Diabetes [Member]
Royalty Percent, Licensed Technology Covered by Patent															3%
License Agreement [Member] \| University of Pittsburgh [Member] \| Maximum [Member] \| Represents Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 and 2 Diabetes [Member]
Royalty Percent, Licensed Technology Covered by Patent													3%
Development and Manufacturing of GMP Grade Materials [Member]
Costs and Expenses									$ 0	$ 2,200,000
Development Services Agreement, Expected Total Project Cost														$ 4,500,000
Contract Payments, Returned to Company	$ 1,300,000

Note 8 - Subsequent Events (Det

Note 8 - Subsequent Events (Details Textual) - USD ($)		3 Months Ended							9 Months Ended
Note 8 - Subsequent Events (Details Textual) - USD ($)	Oct. 01, 2024	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Proceeds from Issuance of Common Stock									$ 8,029,143	$ 10,593,373
The 2023 ATM Facility [Member]
Stock Issued During Period, Shares, New Issues (in shares)			2,149,417						2,318,450
Proceeds from Issuance of Common Stock			$ 1,215,105						$ 2,117,752
The 2023 ATM Facility [Member] \| Forecast [Member]
Stock Issued During Period, Shares, New Issues (in shares)		3,013,916
Proceeds from Issuance of Common Stock		$ 1,286,014
Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)			5,000	5,000	36,375	125	125	125
Scientific Advisory Board Chairman [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)			5,000			125			10,125	375
Proceeds from Issuance of Common Stock						$ 4,800				$ 17,150
Scientific Advisory Board Chairman [Member] \| Subsequent Event [Member] \| Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)	5,000